Baupost Group has led another round for Wren Therapeutics, a spinout of Cambridge and Lund universities.
Wren Therapeutics, a UK-based small molecule and antibody treatment developer based on research at University of Cambridge and Lund University, closed a £12.4m ($17m) funding round today led by hedge fund Baupost Group.
LifeForce Capital, Schooner Capital and Industry Ventures also provided capital.
Founded in 2016, Wren Therapeutics is working on treatments for diseases caused by protein misfolding. It will use the money to advance its two lead assets – potential therapies for Alzheimer’s and Parkinson’s – towards the clinic.
Andrew von Eschenbach, the commissioner of US regulator Food and Drug Administration under the second George W. Bush administration, and Owen Hughes, chief executive of biopharmaceutical firm Cullinan Management, have been appointed to the board of directors.
Baupost already led a $23.3m series A round in 2019, when LifeForce Ventures and assorted angel investors also took part.
